This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of bromocriptine
PDMED_BROMOCRIPTINE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
59 |
4. Check minimum number of events
Min. number of events
3
|
59 |
5. Include endpointsNone |
59 |
6. Filter based on genotype QC (FinnGen only) |
59 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of bromocriptine
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 59 | 28 | 31 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 52.57 | 50.05 | 54.86 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 54
- Matched controls
- 539
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04BC01
ATC
bromocriptine; oral
+∞
75.6
54
*
G02CB01
ATC
bromocriptine; systemic
830.6
54.1
45
*
N04BD01
ATC
selegiline; oral
90.2
20.8
22
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
37.8
19.1
24
11
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
31.9
18.2
24
13
G20
ICD-10 Finland
Parkinson disease
35.1
18.0
23
11
E22.1
ICD-10 Finland
Hyperprolactinaemia
65.6
16.3
18
*
N04BB01
ATC
amantadine; oral
202.6
15.3
15
*
N04BC06
ATC
cabergoline; oral (dopamine agonists)
92.3
13.3
14
*
N04BX02
ATC
entacapone; oral
167.3
13.0
13
*
H02AB09
ATC
hydrocortisone; systemic
40.4
12.4
15
5
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
55.7
11.5
13
*
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
41.8
10.9
13
*
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
+∞
10.8
10
*
N04BC04
ATC
ropinirole; oral
+∞
10.8
10
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
67.6
10.1
11
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
60.1
9.0
10
*
N04BC02
ATC
pergolide; oral
+∞
8.5
8
*
N04BC05
ATC
pramipexole; oral
10.9
8.3
16
20
N04BD02
ATC
rasagiline; oral
+∞
7.5
7
*
G02CB03
ATC
cabergoline; oral (prolactine inhibitors)
+∞
7.5
7
*
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
78.8
6.6
7
*
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
78.8
6.6
7
*
H01CB02
ATC
octreotide; parenteral
+∞
6.4
6
*
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
+∞
6.4
6
*
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
6.4
6
*
193
Kela drug reimbursment
Rasagiline
+∞
6.4
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
17
37
6.05
8.00
4.8
1.9
286.53
347.09
nmol/l
0.60
17
32
5
15
3.54
1.55
2.6
1.7
38.00
44.53
nmol/l
—
5
15
20
290
0.53
1.45
3.2
2.9
44.60
46.78
u/l
0.07
20
271
9
49
1.98
1.04
3.1
3.8
—
—
—
0
0
9
49
1.98
1.04
1.6
1.5
—
—
—
0
0
20
141
1.63
0.91
2.4
2.4
27.45
29.40
u/l
0.15
20
134
19
134
1.62
0.85
2.4
2.7
0.28
0.18
e6/l
0.37
14
95
21
273
0.64
0.82
3.0
4.7
5.75
6.72
mmol/l
3.48
21
253
11
167
0.58
0.82
2.1
3.9
—
—
—
0
0
9
53
1.82
0.80
1.6
1.6
—
—
—
0
0
5
24
2.18
0.76
3.6
1.6
—
—
—
0
0
5
26
2.01
0.72
2.0
2.5
213.60
117.05
ng/l
—
5
21
5
26
2.01
0.72
7.2
1.9
4.24
4.40
pmol/l
—
5
20
10
151
0.59
0.72
2.3
1.9
220.40
362.04
u/l
—
10
145
5
27
1.93
0.70
3.6
1.7
—
—
—
0
0
0
20
0.00
0.61
0.0
2.1
—
—
—
0
0
0
19
0.00
0.61
0.0
1.9
—
—
—
0
0
0
22
0.00
0.60
0.0
1.5
—
—
—
0
0
26
211
1.42
0.58
3.3
6.4
1.23
1.21
mmol/l
0.41
17
176
23
183
1.42
0.57
2.8
2.1
77.31
96.43
pmol/l
1.13
15
98
20
162
1.35
0.43
2.5
3.0
—
—
—
0
0
0
15
0.00
0.42
0.0
1.4
—
0.14
—
0
5
0
16
0.00
0.42
0.0
1.4
—
—
—
0
0
41
371
1.34
0.41
21.0
15.4
40.75
39.92
%
0.52
32
257
45
481
0.73
0.38
23.6
22.2
134.82
135.00
g/l
0.03
45
471
6
45
1.37
0.35
1.8
2.8
2.83
6.09
umol/l
—
6
37
32
355
0.78
0.34
4.9
7.3
87.72
76.37
u/l
1.23
32
333
7
98
0.68
0.34
1.4
1.7
0.62
1.24
mg/l
—
7
84
21
243
0.79
0.31
3.1
6.5
10.43
10.42
umol/l
0.00
21
229
22
252
0.80
0.30
2.1
2.9
—
—
—
0
0
10
78
1.34
0.26
1.6
1.7
—
—
—
0
0
41
436
0.80
0.25
13.2
15.4
25.75
24.04
mg/l
0.14
35
362
11
88
1.31
0.24
1.9
1.9
813.00
1370.87
nmol/l
—
6
64
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.5
—
87.58
—
0
6
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.5
—
—
—
0
0
39
407
0.88
0.12
14.2
14.8
81.46
76.85
ml/min/173m2
0.77
34
327
45
463
0.88
0.09
15.0
18.3
73.82
79.48
umol/l
1.00
45
463
23
243
0.91
0.07
7.4
9.9
4.08
4.25
e9/l
0.09
17
216
14
150
0.91
0.05
2.2
2.4
58.00
51.40
u/l
0.22
14
141
14
150
0.91
0.05
4.0
4.7
22.00
22.53
%
—
6
86
10
103
0.96
0.00
1.7
1.9
608.80
437.36
pmol/l
—
5
83
45
453
0.97
0.00
15.8
17.8
139.58
139.61
mmol/l
0.04
45
436
10
104
0.95
0.00
1.8
2.5
—
—
—
0
0
45
454
0.96
0.00
16.0
17.7
3.94
4.00
mmol/l
0.67
45
440
19
192
0.98
0.00
3.2
4.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
205.93
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
105.57
—
0
7
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
92.17
—
0
6
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
8.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
5.8
—
83.38
—
0
8
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
5
56
0.88
0.00
1.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
13.84
—
0
5
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
5
58
0.85
0.00
1.2
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
16.00
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_BROMOCRIPTINE – Use of bromocriptine
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).